• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

    12/11/24 7:00:00 AM ET
    $CYTH
    $RFL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance
    Get the next $CYTH alert in real time by email

    NEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024.

    "We anticipate proceeding to a shareholder vote on our pending merger agreement with Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the first calendar quarter of 2025 and closing promptly post shareholder approvals. Upon closing of the merger, the Company intends to focus its strategic efforts and resources on what will then be the Company's lead clinical program and core asset, Trappsol® Cyclo™. Accordingly, we are currently evaluating our other operating entities and portfolio of assets," said Bill Conkling, CEO of Rafael Holdings. Bill added, "We are encouraged that Cyclo Therapeutics has fully enrolled its pivotal Phase 3 study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, and results from the 48-week interim analysis are expected in the middle of 2025. Despite recent FDA approvals of other treatments for NPC Type C1, we believe that Trappsol® Cyclo™ has the potential to be a market leader."

    Rafael Holdings, Inc. First Quarter Fiscal Year 2025 Financial Results

    As of October 31, 2024, we had cash, cash equivalents and marketable securities of $54.3 million.

    For the three months ended October 31, 2024, we recorded a net loss attributable to Rafael Holdings of $9.0 million, or $0.37 per share, versus a net loss of $3.6 million, or $0.15 per share in the year ago period. The year over year increase in losses was attributable to the combined unrealized losses of $6.0 on the Company's investment in Cyclo as well as in the convertible notes receivable from Cyclo, versus $2.1 million in unrealized losses on the Company's investment in Cyclo in the year ago period.

    Research and development expenses were $1.3 million for the three months ended October 31, 2024, compared to $0.5 million in the year ago period. The year over year increase relates to activity at Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024.

    For the three months ended October 31, 2024, general and administrative expenses were $2.5 million. For the same period in the prior year, general and administrative expenses were $2.0 million. The increase was primarily due to additional expenses from Cornerstone and Day Three, as well as increased professional fees related to the proposed Cyclo merger.

    About Rafael Holdings, Inc.

    Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies including an investment in (and planned merger with) Cyclo Therapeutics Inc. (NASDAQ:CYTH), a biotechnology company dedicated to developing Trappsol® Cyclo™, which is being evaluated in clinical trials, including an ongoing Phase 3 trial for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal, and progressive genetic disorder.  Rafael also holds a majority equity interest in LipoMedix Pharmaceuticals Ltd. a clinical stage pharmaceutical company, Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, a majority interest in Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, a majority interest in Rafael Medical Devices, LLC., an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings enabling them to bring to market better, cleaner, more precise and predictable versions by utilizing Day Three's pharmaceutical-grade technology and innovation like Unlokt™. The Company's primary focus is to expand our investment portfolio through opportunistic and strategic investments including therapeutics, which address high unmet medical needs. Upon closing of the planned merger with Cyclo Therapeutics, the Company intends to focus its efforts on making Trappsol®Cyclo™ its lead clinical program.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Contact:

    Barbara Ryan

    [email protected]

    (203) 274-2825



     RAFAEL HOLDINGS, INC.     
     CONSOLIDATED BALANCE SHEETS     
      (in thousands, except share and per share data)     
          
       October 31, 2024 July 31, 2024
         (audited)
     ASSETS    
          
     CURRENT ASSETS    
     Cash and cash equivalents $8,159  $2,675 
     Available-for-sale securities  46,138   63,265 
     Interest receivable  438   515 
     Convertible note receivables, due from Cyclo  12,603   5,191 
     Accounts receivable, net of allowance for credit losses of $245 at October 31, 2024 and July 31, 2024  201   426 
     Prepaid expenses and other current assets  2,942   430 
     Total current assets  70,481   72,502 
          
     Property and equipment, net  2,078   2,120 
     Investments - Hedge Funds  -   2,547 
     Investments – Cyclo  7,645   12,010 
     Convertible note receivable classified as available-for-sale  1,161   1,146 
     Goodwill  3,050   3,050 
     Intangible assets, net  1,818   1,847 
     In-process research and development  1,575   1,575 
     Other assets  27   35 
     TOTAL ASSETS $87,835  $96,832 
          
     LIABILITIES AND EQUITY    
     CURRENT LIABILITIES    
     Accounts payable $2,700  $2,556 
     Accrued expenses  1,379   1,798 
     Convertible notes payable  614   614 
     Other current liabilities  112   113 
     Due to related parties  734   733 
     Installment note payable  1,700   1,700 
     Total current liabilities  7,239   7,514 
          
     Accrued expenses, noncurrent  3,138   2,982 
     Convertible notes payable, noncurrent  74   73 
     Other liabilities  —   5 
     TOTAL LIABILITIES  10,451   10,574 
          
     COMMITMENTS AND CONTINGENCIES    
          
     EQUITY    
     Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of October 31, 2024 and July 31, 2024  8   8 
     Class B common stock, $0.01 par value; 200,000,000 shares authorized, 24,135,035 issued and 23,785,043 outstanding (excluding treasury shares of 101,487) as of October 31, 2024, and 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024  238   238 
     Additional paid-in capital  280,359   280,048 
     Accumulated deficit  (210,749)  (201,743)
     Treasury stock, at cost; 101,487 Class B shares as of October 31, 2024 and July 31, 2024  (168)  (168)
     Accumulated other comprehensive income related to unrealized income on available-for-sale securities  132   111 
     Accumulated other comprehensive income related to foreign currency translation adjustment  3,696   3,691 
     Total equity attributable to Rafael Holdings, Inc.  73,516   82,185 
     Noncontrolling interests  3,868   4,073 
     TOTAL EQUITY  77,384   86,258 
          
     TOTAL LIABILITIES AND EQUITY $87,835  $96,832 
          





    RAFAEL HOLDINGS, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
     (unaudited, in thousands, except share and per share data)
        
        
     Three Months Ended October 31,
      2024   2023 
    Revenues$128  $68 
        
    Cost of infusion technology revenue 37   - 
    SG&A Expenses 2,523   2,040 
    R&D Expenses 1,326   489 
    Depreciation and amortization 86   17 
    Operating Loss (3,844)  (2,478)
        
    Interest income 568   582 
    Realized gain on available-for-sale securities 194   177 
    Realized loss on investment in equity securities -   (46)
    Realized gain on investments - Cyclo -   424 
    Unrealized loss on investments - Cyclo (4,365)  (2,124)
    Unrealized loss on convertible notes receivable, due from Cyclo (1,588)  - 
    Unrealized loss on investments - Hedge Funds -   (166)
    Interest expense (162)  - 
    Other income (2)  93 
    Loss before Incomes Taxes (9,199)  (3,538)
    Taxes (12)  (6)
    Equity in loss of Day Three Labs Inc. -   (216)
        
    Consolidated net loss (9,211)  (3,760)
    Net loss attributable to noncontrolling interests (205)  (122)
    Net loss attributable to Rafael Holdings, Inc.$(9,006) $(3,638)
        
        
    Loss per share   
    Basic and diluted (0.37)  (0.15)
       Loss per basic common share$(0.37) $(0.15)
        
    Weighted average shares in calculation 25,062,854   23,644,647 
        


    Primary Logo

    Get the next $CYTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYTH
    $RFL

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $CYTH
    $RFL
    Financials

    Live finance-specific insights

    See more
    • Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

      Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy Rafael Holdings to Host Conference Call Today at 8:00 a.m. ET NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals") as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phas

      10/28/21 7:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $CYTH
    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025. Former holders of Cyclo Therapeutics, Inc. who did not hold shares in street name and have not submitted their letter of transmittal to Equiniti Trust Company LLC (the Company's transfer agent), and wish to participate in the rights offering, should send their

      5/5/25 7:00:00 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants ("Holders") the opportunity to purchase additional shares of Rafael Holdings' Class B common stock, par value $0.01 per share ("Class B Common Stock"), subject to the terms outlined below for an aggregate offering of $25 million. The funds provide the Company additional capital for the potential launch of Trappsol® Cyclo™ in the event of a positive interim result from the 48-week interim analysis of the TransportNPC™ Phase 3 clinical t

      4/29/25 4:30:00 PM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced that, following the merger with Cyclo Therapeutics, Bill Conkling will be stepping down as CEO and assuming an advisory role with the Company. Rafael's Executive Chairman and Chairman of the Board, Howard Jonas will assume the role of CEO. During his tenure as CEO, Bill played a pivotal role in identifying investment opportu

      4/24/25 4:15:00 PM ET
      $RFL
      Real Estate
      Finance

    $CYTH
    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      9/30/24 5:40:03 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      6/18/24 6:12:11 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/24 2:44:54 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CYTH
    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Conkling William was granted 27,454 units of Class B Common Stock, increasing direct ownership by 5% to 564,455 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      4/24/25 3:18:53 PM ET
      $RFL
      Real Estate
      Finance
    • New insider Sieger Markus claimed ownership of 155,182 units of Class B Common Stock (SEC Form 3)

      3 - Rafael Holdings, Inc. (0001713863) (Issuer)

      4/2/25 10:56:32 AM ET
      $RFL
      Real Estate
      Finance
    • Chief Financial Officer Polinsky David covered exercise/tax liability with 2,378 units of Class B Common Stock, decreasing direct ownership by 1% to 193,540 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      3/25/25 4:40:08 PM ET
      $RFL
      Real Estate
      Finance

    $CYTH
    $RFL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

      CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. ("Cornerstone" or the "Company"), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company's Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics. "Dr. Locasale is an internationally recognized leader in the use of metabolomics approaches to study cancer biology and metabolism," said Sanjeev Luther, President & CEO at Cornerstone Pharmaceutical

      7/6/22 8:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $CYTH
    $RFL
    SEC Filings

    See more
    • Rafael Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      5/6/25 4:49:29 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form 424B3 filed by Rafael Holdings Inc.

      424B3 - Rafael Holdings, Inc. (0001713863) (Filer)

      5/6/25 4:40:50 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form 8-K/A filed by Rafael Holdings Inc.

      8-K/A - Rafael Holdings, Inc. (0001713863) (Filer)

      5/5/25 7:15:49 AM ET
      $RFL
      Real Estate
      Finance

    $CYTH
    $RFL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

      Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously

      2/10/21 8:07:06 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care